Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc.

Kahn Swick & Foti (KSF) said it continues an investigation into Inspire Medical Systems (NYSE: INSP) following the company’s August 2025 disclosure that the launch of its Inspire V device faced an “elonga—” delay despite prior assurances it had met regulatory, technical, and commercial prerequisites. The news suggests ongoing legal/regulatory scrutiny but does not yet provide quantified financial damage or resolution.

Analysis

This is less about the legal headline than about credibility damage to a premium-growth story. When a growth med-tech company has to revisit a launch timeline after repeatedly signaling readiness, the market tends to re-rate the whole forward model: lower near-term procedure growth, slower surgeon/physician adoption, and a higher discount rate on long-duration revenue assumptions. That matters disproportionately for INSP because the stock is priced on continued category expansion, not just on current revenue.

The immediate loser is INSP’s multiple; the second-order winner is ResMed (RMD), which can absorb patients who stay on established CPAP pathways while Inspire’s rollout friction persists. Any delay also bleeds into the commercial funnel: sales reps, training slots, and inventory commitments are all easier to defer than to accelerate, so a launch slip can push out revenue and margin leverage for multiple quarters. If channel partners sense uncertainty, they will prioritize better-supported alternatives, which can quietly slow share gains even without a catastrophic product issue.

The key catalyst path is the next earnings print and any quantified update on launch cadence, implant volumes, and gross margin bridge. If management can show the delay is a narrow timing issue with no change to full-year procedure guidance, the stock can bounce; if not, the market will likely keep trimming 2025-26 growth estimates for months. The contrarian miss is that consensus may still be underpricing how much of INSP’s valuation depends on execution trust rather than just device demand.

Key Decisions for Investors

• Short INSP on any relief rally into the next earnings update; treat this as a 1-3 month credibility trade with downside if management cannot quantify an unchanged launch ramp.
• Buy 1-3 month INSP put spreads 10-15% out of the money to express event risk with defined premium burn; best entered after any intraday bounce on headline fatigue.
• Pair trade: short INSP / long RMD for 1-3 months to express share-recapture risk from a delayed rollout; thesis breaks if INSP restores launch timing and reiterates full-year procedure guidance.
• Set a watch item on next quarterly guidance for procedure growth, system placements, and margin; if any of those are cut, expect further multiple compression over the following 6-18 months.
• If borrow is tight or options are expensive, reduce to a tactical short only and avoid size until the company quantifies whether this is a one-quarter slip or a structural launch problem.